natgillin/translations-raw huggingface dataset:
The combination of avanafil and Symtuza is contraindicated (see section 4.3).
Sočasna uporaba avanafila in zdravila Symtuza je kontraindicirana (glejte poglavje 4.3).
Based on theoretical considerations bosentan is expected to decrease darunavir and/or cobicistat plasma concentrations.
Glede na teoretična izhodišča je mogoče pričakovati, da bosentan znižuje plazemske koncentracije darunavirja in/ali kobicistata(indukcija CYP3A).
Based on theoretical considerations DRV/COBI may alter norethindrone plasma concentrations.
Glede na teoretična izhodišča je mogoče pričakovati, da kombinacija darunavirja/kobicistata lahko spreminja plazemske koncentracije noretindrona.
ERGOT DERIVATIVES e.g.
Po peroralnem jemanju s
(CYP3A inhibition) Concentrations of clarithromycin may be increased upon co-administration with DRV/COBI.
Pri sočasni uporabi kombinacije darunavirja/kobicistata in klaritromicina se lahko koncentracija klaritromicina zviša (zaviranje CYP3A).
Based on theoretical consideration, St. John's wort may substantially decrease DRV/COBI (CYP3A4 induction) and TAF exposures.
Glede na teoretična izhodišča je mogoče pričakovati , da šentjanževka pomembno znižuje koncentracijo kombinacije darunavirja/kobicistata (indukcija CYP3A4) in zmanjša izpostavljenost alafenamidtenofoviratu (indukcija P-glikoproteina).
Based on theoretical considerations DRV/COBI is expected to increase salmeterol plasma concentrations.
Glede na teoretična izhodišča je mogoče pričakovati, da kombinacija darunavirja/kobicistata zvišuje plazemske koncentracije salmeterola v plazmi (zaviranje CYP3A).
Clinical monitoring is recommended when co-administering Symtuza with these analgesics.
Pri sočasni uporabi zdravila Symtuza z navedenimi analgetiki je priporočljivo klinično spremljanje bolnika.
Omeprazole
Starostniki
How to store Symtuza
Shranjevanje zdravila Symtuza
Symtuza might increase the risk for elevated potassium levels by drospirenone.
Sočasno dajanje zdravila Symtuza in drospirenona lahko zveča tveganje za zvišanje koncentracije kalija.
A higher dose may be needed in children.
Pri otrocih bo morda potreben večji odmerek.
Further information on NovoSeven can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/novoseven.
Nadaljnje informacije o zdravilu NovoSeven so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/novoseven.
The main measure of effectiveness was the number of bleeding episodes that were controlled effectively.
Glavno merilo učinkovitosti je bilo število učinkovito nadzorovanih epizod krvavitev.
NovoSeven received a marketing authorisation valid throughout the EU on 23 February 1996.
Zdravilo NovoSeven je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 23. februarja 1996.
What measures are being taken to ensure the safe and effective use of NovoSeven?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila NovoSeven?
The European Medicines Agency decided that NovoSeven's benefits are greater than its risks and it can be authorised in the EU..
Evropska agencija za zdravila je zaključila, da so koristi zdravila NovoSeven večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
Other information about NovoSeven
Druge informacije o zdravilu NovoSeven
• congenital factor VII deficiency;
• prirojenim pomanjkanjem faktorja VII;
As for all medicines, data on the use of NovoSeven are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila NovoSeven stalno spremljajo.
Why is NovoSeven authorised in the EU?
Zakaj je zdravilo NovoSeven odobreno v EU?
An overview of NovoSeven and why it is authorised in the EU
Pregled zdravila NovoSeven in zakaj je odobreno v EU
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of NovoSeven have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila NovoSeven upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Patients or carers may be able to give NovoSeven themselves after suitable training.
Bolniki ali negovalci si lahko po ustreznem usposabljanju zdravilo injicirajo sami.
Because factor VII acts directly on factor X, independently from factors VIII and IX, NovoSeven can be used in haemophilia patients who have developed inhibitors to factor VIII or IX.
Ker faktor VII učinkuje neposredno na faktor X, in sicer neodvisno od faktorjev VIII in IX, se lahko zdravilo NovoSeven uporablja pri bolnikih s hemofilijo, pri katerih so se razvili zaviralci faktorjev VIII ali IX.
What benefits of NovoSeven have been shown in studies?
Kakšne koristi je zdravilo NovoSeven izkazalo v študijah?
What is NovoSeven and what is it used for?
Kaj je zdravilo NovoSeven in za kaj se uporablja?
It is used in patients with the following conditions:
Ne smejo ga uporabljati bolniki z naslednjimi vrstami obolenj:
In the body, factor VII is involved in blood clotting.
Faktor VII v telesu sodeluje pri strjevanju krvi.
It activates another factor called factor X, which starts the clotting process.
Aktivira drug faktor, imenovan faktor X, ki sproži proces strjevanja krvi.
Side effects reported with NovoSeven are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu NovoSeven, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
NovoSeven must not be used in people who are hypersensitive (allergic) to eptacog alfa, to mouse, hamster or cow proteins, or to any of the other ingredients.
Zdravila NovoSeven ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) eptakog alfa, mišje, hrčkove ali goveje beljakovine ali katero koli drugo sestavino zdravila.
• Glanzmann's thrombasthenia (a rare bleeding disorder) who cannot be treated with a transfusion of platelets (components that help the blood to clot).
• Glanzmannovo trombastenijo (redko motnjo strjevanja krvi), ki jih ni mogoče zdraviti s transfuzijo trombocitov (sestavino krvi, ki pomaga pri strjevanju krvi).
What are the risks associated with NovoSeven?
Kakšna tveganja so povezana z zdravilom NovoSeven?
However the following side effects may affect between 1 and 10 patients in 1,000: venous thromboembolic events (problems caused by blood clots in the veins), rash, pruritus (itching), urticaria (hives), fever and reduced effectiveness of treatment.
Vendar so bili pri 1 do 10 bolnikih od 1 000 opaženi naslednji neželeni učinki: venski trombembolični dogodki (težave zaradi krvnih strdkov v venah), izpuščaji, pruritus (srbenje), urtikarija (srbeči izpuščaji), zvišana telesna temperatura in manjša učinkovitost zdravljenja.
For more information about using NovoSeven, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila NovoSeven glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Data on the use of NovoSeven in patients with Glanzmann's thrombasthenia were obtained from a registry of patients treated with the medicine, which showed that treatment with NovoSeven was successful in 79% of the bleeding episodes (262 out of 333) and 88% of the surgeries (140 out of
Podatki o uporabi zdravila NovoSeven pri bolnikih z Glanzmannovo trombastenijo so bili pridobljeni iz registra bolnikov, zdravljenih z zdravilom, ki je pokazal, da je bilo zdravljenje z zdravilom NovoSeven uspešno v 79 % (262 od 333) epizod krvavitev in pri 88 % (140 od 159) kirurških posegov.
The active substance in NovoSeven, eptacog alfa, is almost identical to a human protein called factor VII.
Učinkovina v zdravilu NovoSeven, eptakog alfa, je skoraj enaka človeški beljakovini, imenovani faktor VII.
NovoSeven can also be used to replace the missing factor VII in patients with factor VII deficiency.
Zdravilo NovoSeven se lahko uporablja tudi za nadomeščanje manjkajočega faktorja VII pri bolnikih s pomanjkanjem tega faktorja.
Eptacog alfa works in the same way as factor VII.
Eptakog alfa deluje enako kot faktor VII.
By activating factor X, NovoSeven is able to give temporary control of the bleeding disorder.
Z aktiviranjem faktorja X zdravilo NovoSeven vzpostavi začasen nadzor nad motnjo strjevanja krvi.
In another study in 60 patients with mild to moderate bleeding episodes, which investigated whether NovoSeven could be used in the home setting, 90% of the bleeding episodes were controlled effectively.
V drugi študiji, v katero je bilo vključenih 60 bolnikov z blagimi do zmernimi epizodami krvavitev in v kateri so proučevali, ali bi se lahko zdravilo NovoSeven uporabljalo v domačem okolju, je bilo učinkovito nadzorovanih 90 % epizod krvavitev.
NovoSeven can only be obtained with a prescription and treatment and should be started under the supervision of a doctor who has experience in the treatment of haemophilia or bleeding disorders.
Predpisovanje in izdaja zdravila NovoSeven je le na recept, zdravljenje z njim pa se sme uvesti samo pod nadzorom zdravnika z izkušnjami z zdravljenjem hemofilije ali motenj strjevanja krvi.
Side effects with NovoSeven are not common.
Neželeni učinki zdravila NovoSeven niso pogosti.
• In factor VII deficiency, the dose is 15 to 30 micrograms/kg every 4 to 6 hours until the bleeding is controlled.
• Pri pomanjkanju faktorja VII znaša odmerek med 15 in 30 mikrogramov na kilogram telesne mase vsakih štiri do šest ur, dokler se ne vzpostavi nadzor nad krvavitvijo.
NovoSeven has been studied in patients with haemophilia and in patients with factor VII deficiency.
Zdravilo NovoSeven je bilo raziskano pri bolnikih s hemofilijo in bolnikih s pomanjkanjem faktorja VII.
NovoSeven is a medicine used to treat and to prevent bleeding after surgical procedures.
Zdravilo NovoSeven se uporablja za zdravljenje in preprečevanje krvavitev po kirurških posegih.
It is available as a powder and solvent that are made up into a solution to be injected into a vein.
Zdravilo je na voljo v obliki praška in vehikla za pripravo raztopine za injiciranje v veno.
• In Glanzmann's thrombasthenia, the dose is 90 micrograms/kg every 2 hours, for at least three doses.
• Pri Glanzmannovi trombasteniji znaša odmerek 90 mikrogramov na kilogram telesne mase vsaki dve uri, pri čemer je treba injicirati najmanj tri odmerke.
• acquired haemophilia (a bleeding disease caused by the development of inhibitors to factor VIII);
• pridobljeno hemofilijo (motnjo strjevanja krvi, ki jo sproži razvoj zaviralcev faktorja VIII);
In a study involving 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
V največji študiji, ki je zajela 61 bolnikov s hemofilijo z zaviralci, je bilo zdravilo NovoSeven učinkovito pri 84 % od 57 resnih krvavitev in pri 59 % od 38 krvavitev zaradi kirurškega posega.
How is NovoSeven used?
Kako se zdravilo NovoSeven uporablja?
• In haemophilia, the dose is 90 micrograms per kilogram body weight, repeated every 2 to 3 hours until the bleeding is controlled.
• Pri hemofiliji se daje odmerek 90 mikrogramov na kilogram telesne mase vsake dve do tri ure, dokler se ne vzpostavi nadzor nad krvavitvijo.
NovoSeven contains the active substance eptacog alfa.
Zdravilo NovoSeven vsebuje učinkovino eptakog alfa.
For the full list of side effects of NovoSeven, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila NovoSeven, glejte navodilo za uporabo.
How does NovoSeven work?
Kako zdravilo NovoSeven deluje?
270 micrograms/kg may be used in adults with a mild or moderate bleeding episode.
Pri odraslih z blago do zmerno epizodo krvavitve se sme uporabiti enkraten odmerek 270 mikrogramov na kilogram telesne mase.
• congenital haemophilia (a bleeding disorder present from birth) who have developed or are expected to develop ‘inhibitors' (antibodies) against factor VIII or IX;
• prirojeno hemofilijo (motnjo strjevanja krvi od rojstva), pri katerih so se razvili ali je pričakovati,
Do not pass it on to others.
Ne smete ga dajati drugim.
The updated guidelines were established during the Maastricht 22000 Consensus meeting.
Posodobljene smernice so bile določene na 2. konsenz konferenci v Maastrichu 2000.
Effect*
Učinek*
- This medicine has been prescribed for you.
- Zdravilo je bilo predpisano vam osebno.
The expiry date refers to the last day of that month.
Datum izteka roka uporabnosti se nanaša na zadnji dan v mesecu.
Please follow your doctor's recommendations
Upoštevajte zdravnikova priporočila.
Benefit/Risk considerations
Razmerje med koristmi/tveganji
Since then new data became available that necessitated an update of the original guidelines in order to provide practical management guidelines that would be acceptable across clinical practice, both in primary care and the specialist level.
Od takrat so bili na razpolago dani novi podatki zaradi katerih je bilo potrebno smernice posodobiti , da bi tako zagotovili praktična priporočila za obvladovanje, ki bi bila sprejemljiva po vsej klinični praksi, tako v osnovnem zdravstvu kot na specialistični ravni.
This was not seen in monkeys, dogs or mice.
Tega učinka niso opazili pri opicah, psih ali miših.
After eight days of repeated administration the reduction is about 85%.
Po osmih dneh ponavljajoče se uporabe je zmanjšanje približno 85 %.
The side effects listed in section 4 may occur in a more severe form.
Neželeni učinki, navedeni v poglavju 4 se lahko pojavijo v hujši obliki.
Individual patients may receive a clinically relevant decrease.
Pri posameznih bolnikih lahko pride do klinično pomembnega zmanjšanja.
LICONSA, Liberación Controlada de Sustancias Activas, S.A.
LICONSA, Liberación Controlada de Sustancias Activas, S.A. Avda.
However, in order to avoid treatment failure, local antibacterial resistance patterns and local guidelines should be considered.
Da pa bi se lažje izognili neuspešnim zdravljenjem, je treba upoštevati lokalne vzorce antibakterijske rezistence in lokalne smernice.
Consideration should be given to official local guidance (e.g. national recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial agents.
Bodite pozorni na uradne smernice (npr. državna priporočila) glede bakterijske rezistence in ustrezne uporabe ter predpisovanja protibakterijskih sredstev.
Miralcampo, Nº 7, Polígono Industrial Miralcampo, 19200 Azuqueca de Henares (Guadalajara), Spain
Miralcampo, Nş 7, Polígono Industrial Miralcampo, 19200 Azuqueca de Henares (Guadalajara), Španija
The capsules are swallowed whole with liquid.
Kapsule se pogoltnejo cele s tekočino.
(See Section 4.2 Posology and Method of Administration)
(Glejte poglavje 4.2 Odmerjanje in način uporabe)
Bioavailability after a single dose of 30 mg and after repeated daily administration is 80-90%.
Biološka uporabnost po enkratnem 30-miligramskem odmerku in po ponavljajoči se dnevni uporabi je 80-90 %.
This medicine has the best effect when taken into empty stomach.
Zdravilo je najučinkovitejše, kadar ga bolnik vzame na prazen želodec
These gastro-resistant capsules are available in blister packs containing 14, 28, 56 or 98 capsules.
Te gastrorezistentne kapsule so na voljo v pretisnih omotih po 7, 14, 28, 56 ali 98 kapsul.
The effects of overdose of lansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instructions for treatment cannot be given.
Učinki prevelikega odmerjanja lansoprazola pri človeku niso znani (čeprav je akutna toksičnost verjetno majhna), zato ni mogoče dati navodil za zdravljenje.
It was pointed out that treatment should be thought of as a package, which considers first- and second-line eradication therapies together.
Poudarjeno je bilo, da je treba o zdravljenju razmišljati kot o paketu, v katerem sta zdravljenji prve in druge izbire za eradikacijo bakterije obravnavani skupaj.
This can reduce your responsiveness when driving a vehicle or operating machinery.
To lahko zmanjša odzivnost pri vožnji ali upravljanju strojev.
Dosage and duration of combined administration
Odmerjanje in trajanje kombinirane uporabe
Elimination of lansoprazole in the elderly is slightly delayed.
Izločanje lansoprazola pri starejših osebah je nekoliko upočasnjeno.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development.
Študije na živalih ne kažejo neposrednih ali posrednih škodljivih vplivov na nosečnost, razvoj zarodka/plodu, porod ali postnatalni razvoj.
The following undesirable effects have been observed during treatment with lansoprazole with the following frequencies: Common (>1/100, <1/10), uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000), very rare (<1/10,000) including isolated reports.
Pri zdravljenju z lansoprazolom so opazili naslednje neželene učinke z naslednjo pogostostjo: pogosti (>1/100, <1/10), občasni (>1/1.000, <1/100), redki (>1/10.000, <1/1.000), zelo redki (<1/10.000) vključno s posameznimi primeri.
The influence of this combined administration has not yet been investigated systemically.
Učinka kombiniranega zdravljenja še niso sistematično raziskali.
Because of limited safety data for patients on maintenance treatment for longer than 1 year, regular review of the treatment and a thorough benefit risk assessment should regularly be performed in these patients.
Zaradi omejenih podatkov o varnosti bolnikov na vzdrževalnem zdravljenju, ki traja dlje kot eno leto, je treba redno ocenjevati zdravljenje in opraviti temeljito oceno tveganja in koristi.
Lansoprazol CT-Arzneimittel 15 mg, 30 mg, gastro-resistant capsules, hard were referred for arbitration according to Article 29 of Council Directive 2001/83/EC, as amended, following concerns raised by Germany during a Mutual Recognition Procedure with Finland acting as Reference Member state.
Zdravilo Lansoprazol CT-Arzneimittel 15-mg, 30-mg gastrorezistentne kapsule, trde, je bilo napoteno na arbitražni postopek v skladu s členom 29 Direktive Sveta 2001/83/ES, kakor je bila spremenjena, zaradi zadržkov, ki jih je predložila Nemčija v okviru postopka medsebojnega priznavanja s Finsko, ki je bila referenčna država članica.
Lansoprazol-CT has minor or moderate influence on the ability to drive and use machines.
Lansopazol -CT ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
4.1 Therapeutical indications
4.1 Terapevtske indikacije
There is no change in half-life during treatment.
Med zdravljenjem se razpolovni čas ne spreminja.
The elimination half-life of lansoprazole is 1.0-2.0 hours.
Razpolovni čas izločanja lansoprazola je 1,0 do 2,0 uri.
The usual dose is
Običajni odmerek
The stomach ulcer usually heals within 4 weeks.
Razjede želodca se navadno pozdravijo v 4 tednih.
7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 and 100x1 capsules Not all pack sizes may be marketed.
Al/Al (OPA/Al/PVC//PVC/Al/PET) pretisni omot 7, 10, 10x1, 14, 14x1, 20, 28, 28x1, 30, 30x1, 56, 56x1, 60, 98, 98x1, 100 in 100x1 kapsula Na trgu ni vseh navedenih pakiranj.
The following interactions between lansoprazole and one/two antibiotics used in eradication therapy have been found so far:
Do sedaj so odkrili naslednje interakcije med lansoprazolom in enim/dvema antibiotikoma, ki se uporabljajo v eradikacijskem zdravljenju:
Colitis, stomatitis and black tongue.
Kolitis, stomatitis in črn jezik.
The effect of simultaneous administration of lansoprazole and various antibiotics (particularly clarithromycin) has not been systematically investigated.
Učinka sočasne uporabe lansoprazola in različnih antibiotikov (zlasti klaritromicina) še niso sistematsko raziskali.
After 18 months of treatment retinal atrophy was observed.
Po 18 mesecih zdravljenja so opazili retinalno atrofijo.
About 15-50% of the metabolites are secreted in the urine and the remainder in the faeces.
Približno 15-50 % presnovkov se izloči z urinom, preostanek pa z blatom.
Intake of food slows the absorption rate of lansoprazole and reduces its bioavailability (AUC) by about 25%.
Uživanje hrane upočasni absorpcijo lansoprazola in zmanjša biološko uporabnost (AUC) za približno 25 %.
CYP2C19 is subject to genetic polymorphism and 2-6 % of the population, called poor metabolisers (PMs), are homozygote for a mutant CYP2C19 allele and therefore lacks a functional CYP2C19 enzyme.
CYP2C19 je izpostavljen genetskemu polimorfizmu in 2-6 % populacije, t. i. slabi presnavljalci (PM - "Poor Metaboliser"), so homozigoti za mutantni alel CYP2C19, in zato nimajo funkcionalnega encima CYP2C19.
Increase in cholesterol and triglyceride levels.
Povečanje ravni holesterola in trigliceridov.
If visual disturbances occur during long-term use (>1 year), intake of the medicine should immediately be stopped and an ophthalmologist should be consulted.
Če se pri dolgotrajni uporabi (> 1 leto) pojavijo motnje vida, je treba jemanje zdravila nemudoma prekiniti in se posvetovati z okulistom.
Stevens-Johnson syndrome and toxic epidermal necrolysis.
Stevens-Johnsonov sindrom in toksična epidermalna nekroliza.
Dry mouth or throat and anorexia.
Suha usta in grlo ter anoreksija.
Metronidazole was originally considered as an alternative to amoxicillin but there is now tendency to reserve it for rescue therapy in the case of a first eradication failure.
Metronidazol je bil prvotno mišljen kot alternativa za amoksiciklin, vendar se sedaj čedalje bolj uveljavlja kot rešilno zdravljenje v primeru, ko je zdravljenje prve izbire neuspešno.
The plasma protein binding of lansoprazole is about 95%, but this has not been found to have a significant effect on other protein bound active substances.
Vezava lansoprazola na beljakovine v plazmi je približno 95-%, vendar to ne vpliva na druge zdravilne učinkovine, ki se vežejo na beljakovine v plazmi.
If you have the impression that the effect of Lansoprazol-CT is too strong or too weak, please talk to your doctor.
Če menite, da je učinek zdravila Lansoprazol-CT premočan ali prešibak, se posvetujte z zdravnikom.
Absorption from the duodenum is rapid and plasma peak concentration is achieved within 1.5-2.0 hours.
Absorpcija iz dvanajstnika je hitra in največja koncentracija v plazmi se doseže v 1,5-2,0 urah.
Gynecomastia and galactorrhoea.
Ginekomastija in galaktoreja
These affect the absorption, availability to the body, the breakdown and the elimination of these medicines.
Vplivajo na absorpcijo, razpoložljivost v telesu, presnovo in izločanje teh zdravil.
Lansoprazol-CT should be taken on an empty stomach (before meals).
Zdravilo Lansoprazol-CT morate jemati na prazen želodec (pred obroki).
Reflux oesophagitis may not present, as ulceration and/or visual damage, therefore in certain cases endoscopy alone may not be sufficient.
Refluksni ezofagitis morda ni prisoten v obliki razjede in/ali vidne poškodbe, zato v nekaterih primerih endoskopija ni zadostna.
Erythema multiforme, Petechia, hair loss, hyperhidrosis and purpura .
multiformni eritem, petehija, izguba las, hiperhidroza in purpura.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
Za dodatne informacije o zdravilu pokličite lokalnega predstavnika imetnika dovoljenja za promet z zdravilom.
Due to delayed elimination of lansoprazole in the elderly it may be necessary to administer the treatment in doses of 15-30 mg adjusted to individual requirements.
Zaradi podaljšanega izločanja lansoprazola, bo pri starejših osebah morda treba zdravljenje razdeliti v odmerke po 15-30 mg, glede na potrebe posameznika.
Possible symptoms of lansoprazole overdose can be expected to be similar with adverse drug reactions listed in section 4.8.
Pričakovati je, da bodo morebitni znaki prevelikega odmerjanja lansoprazola podobni neželenim učinkom, navedenim v poglavju 4.8.
If you take more Lansoprazol-CT than you should you should always consult a doctor.
Če ste vzeli večji odmerek zdravila Lansoprazol-CT, kot bi smeli: vedno se posvetujte z zdravnikom.